The Oxford Patent
Profit Plan In 1941, a team of Nobel Prize-winning scientists made a simple mistake that wound up costing them billions... 51 years later, a group of cunning investors uncovered a way to exploit this mistake -- and they've raked in annualized gains of 21% per year ever since. But it's not too late to join them... In fact, one of America's most trusted investors is convinced that this obscure investment opportunity could be your ticket to riches between now and 2017. Read on to discover how you can begin profiting today... November 6, 2010 Dear Fellow Investor, Chances are you've never heard the incredible story I'm about to share with you -- few people have. It begins on June 26, 1941, with two British scientists sneaking several unmarked test tubes out of an Oxford University laboratory, before slipping away to a secret airstrip where they would begin an extremely hazardous trans-Atlantic journey that would ultimately save tens of millions of lives -- perhaps even your own... And frankly, this story is worth reading start to finish for entertainment value alone (I would know, having just finished three entire books on the subject)... But the reason you're going to want to sit up and pay attention right now is that what I'm about to tell you could actually have a significant impact on your net worth between today and July 25, 2017. Nevertheless, I wouldn't want you to waste any time hearing about an opportunity that's not quite right for you... So, before we go any further, let me ask you a simple question... Would you be interested in discovering a publicly traded (yet still practically unheard of) company that... - Owns the rights to an insanely profitable product that commands a full 75% of the U.S. market and has a stranglehold on over 50% of the worldwide market...
- Has grown its revenues by 35% per year over the past 5 years and just saw its sales climb another 13% in the most recent quarter -- despite a brutal global recession...
- Carries a significantly lower P/E ratio than any of its major competitors -- despite consistently turning in much better growth and sporting much higher margins...
- Is sitting on over $5 billion in cash and investments -- and has cranked out another $3 billion in free cash flow in the past year alone...
- Recently announced plans to buy back over $5 billion worth of its own stock over the next three years...
- And has been led by the same visionary CEO since 1996 -- an industry expert who's been with the company for more than two decades?
If the answer is "yes" then I urge you to stick with me for the remainder of this special report. Because over the next few minutes I'm going to give you the full story behind this incredible company and show you why it could help you secure a small fortune over the next six to seven years. Exactly how much are we talking? Well, had you invested just $5,000 in this obscure, yet world-changing company when it first went public, today you'd be sitting on over $155,000. Do the math, and that comes out to 21% per year for 18 years. Granted, I can't guarantee you those kinds of returns going forward, but I can tell you that one of the smartest and most successful investors I've ever met (whose average stock pick is up 100% over the past 8 years) is convinced that right now is the perfect time to get this stock into your portfolio. In order to understand why, we need to look at what was happening in London during the summer of 1941... It was the second year of World War II -- and things were going horribly for the British... Hitler's troops had already stormed right through most of Europe. France had fallen. And it was looking like Russia would be next. To make matters worse, the attack on Pearl Harbor was still months away -- meaning the United States had yet to get involved in the fighting. Needless to say, it was an extremely desperate time for the people of England. And it was this desperation that led the two British scientists I mentioned earlier -- Howard Florey and Norman Heatley -- to do something drastic... For months, they had been working tirelessly with a team of Oxford University researchers to extract a recently discovered yellow powder from cultures of bluish-green mold. Why were they doing this? Well, you see, over the past century, infectious diseases like tuberculosis, scarlet fever, meningitis, and pneumonia had been killing more people than all other causes of death combined. In fact, the influenza epidemic of 1918 ended up killing more than twice the number of people than died in battle during all of World War I. And thanks to the intense fighting and highly unsanitary conditions that both soldiers and civilians were being forced to endure during the early stages of World War II, by 1941, infections had become almost as big a concern as the Nazis. But these scientists were confident they had found a cure that could save millions of lives... Of course, at the time, every last penny the British government had was going to fight Hitler's armies -- and the hard truth was that there simply wasn't anything left over for scientific research. But the Oxford team knew that if they were ever going to transform this mysterious yellow powder into an actual medical breakthrough they were going to need money -- and a whole lot of it. So they decided to take matters into their own hands. And, at first, they agreed on just about everything... That Florey and Heatley would sneak several test tubes filled with freeze-dried mold out of the lab... that they would even rub this mold all over the inside of their jackets in case the test tubes were confiscated... That they would then travel under the cover of darkness to a secret airstrip, where they would board a rattle-trap plane headed to then-neutral Portugal... That they would hole up in a dingy Lisbon hotel room -- being very careful to avoid both German and British spies -- until they could secure the necessary means to board the famous Pan American Clipper for a harrowing 24-hour flight to the United States... That once they were safely on American soil they would meet with everyone from the Rockefeller Foundation to the U.S. Department of Agriculture in an effort to secure the funding they needed to continue their research. But there was one thing they didn't agree on --
and it would end up costing them billions... Several months after the whirlwind tour that took Florey and Heatley everywhere from New Haven, Connecticut, to Beltsville, Maryland, to Peoria, Illinois -- and even to Canada -- something finally happened. But it certainly wasn't what the Oxford team had hoped for... In fact, rather than providing them with the funding they so desperately needed, the U.S. government instead called a secret meeting of the top four U.S. drug companies in December 1941... And not only did the Feds encourage these companies to drop everything and begin mass-producing the substance the Brits had introduced them to, they declared that it was "in America's best interest" to do so. Given that the Japanese had attacked Pearl Harbor just 10 days earlier and catapulted the U.S. into the war, the "big four" had no choice but to agree... So, for the first time in their collective histories, Merck Sharp & Dohme, Charles Pfizer & Co., E.R. Squibb & Sons, and Lederle Laboratories began sharing secrets, openly cooperating, and working toward a common goal... Producing as much penicillin as they possibly could. You see, as it turned out, the Oxford team had been right on the money... Penicillin was, in fact, a miracle drug that could effectively treat everything from pneumonia to meningitis, diphtheria to gonorrhea -- not to mention most of the infections that plagued wounded soldiers on the battlefield. So, it's no wonder that penicillin production shot from 800 million units in the first half of 1943... to 20 billion units in the second half of 1943... to 6.4 TRILLION units by 1945. Nor should it come as any surprise that today penicillin is the most widely used drug in the world -- with U.S. doctors alone writing over 80 million prescriptions for it per year. But here's something that is pretty surprising... Although the British scientists who had worked so hard to develop penicillin went on to win the Nobel Prize, become celebrities on every continent, and even have a crater of the moon named after one of them, they never ended up making a single cent from it. That's because the one thing they never could agree on was whether or not to patent the life-giving substance they had discovered. As a result, it was drug companies like Pfizer and Merck -- and not the team from Oxford -- that went on to make countless billions from this medical breakthrough. But just imagine for a second what would have happened if this brilliant team of scientists had secured an "Oxford Patent"... Better yet, take it one step further, and imagine that YOU had actually had the chance to invest in the team behind this "Oxford Patent" -- and were entitled to a cut of the astronomical profits that followed once their wonder drug hit the market. That really would have been something, wouldn't it? Heck, given the way everything from mutual funds to index funds have performed over the past decade, I'm guessing you'd jump at the chance to get invested in something even a fraction as lucrative. I know I certainly would. Well, you're in luck. Today I'm going to introduce you to just such an opportunity... Granted, the team of scientists behind the company I've been telling you about today didn't discover a wonder drug that's going replace penicillin, but they do hold the patents for two of the world's most highly sought-after -- and profitable -- medicines. And it's no wonder these two drugs are in such high demand... After all, they're the No. 1 most effective treatment for a devastating disease that... - Has already killed some 25 million people -- and currently affects over 33 million more.
- Plagues some 2 million children -- and has orphaned another 14 million across the globe.
- And infects another 2.7 million people per year -- including one person every 9½ minutes in the U.S. alone.
With statistics like that it's not hard to see why former Secretary of State Colin Powell says, "No war on the face of the Earth is more destructive than [this] pandemic"... And it's no wonder former head of the United Nations, Kofi Annan, says this epidemic is, "an unprecedented crisis that requires an unprecedented response." Of course, the good news for both the millions of people afflicted with this fatal disease -- and the shareholders of this company is that so far, the response has been unprecedented. In fact, The Wall Street Journal reports that, over the past seven years, the U.S. government alone has spent $32.3 billion to "put record numbers of patients world-wide on life-lengthening drugs." And a recent article in CQ Weekly says a new bill being sponsored by three Senate Republicans will "take $126 million of unspent funds from last year's economic stimulus and dedicate the funds to purchasing medications for low-income Americans" who suffer from this disease. Plus, President Obama has openly stated a goal of "getting treatment for 85% of patients within three months of their diagnosis" -- and even allocated $25 million to get medication to uninsured patients. Now, whether you agree with his policies or not, the fact of the matter is that any time the President of the United States gets behind a cause you can bet that big money will follow -- especially when Senators from the other side of the aisle are also on board. And don't forget, the company I've been telling you about today controls 75% of the U.S. market for drugs that treat this disease -- not to mention a full 50% of the worldwide market. Which means that a great majority of the money that goes to fight this disease over the coming years will flow right through this company's coffers... and directly into the portfolios of its shareholders. Yet, over the past year or two this company's stock has only gotten cheaper... Why, you ask? Well, in their typical near-sighted, knee-jerk-reaction fashion, many of the "experts" on Wall Street have decided that despite turning in gains north of 3,000% over the past 18 years, this company can suddenly no longer cut the mustard. You see, these loudmouths are arguing that because some of this company's patents expire 6 years from now (on July 25, 2017, to be exact) you should be dumping the stock hand over fist today. (Don't worry, I don't follow the logic there, either.) But what they seem to have overlooked is the fact that not only were this company's sales up a healthy 13% last quarter, but revenues from one of its two main drugs soared an even more impressive 23% -- despite a brutal economy. And I guess they must have missed the part of the conference call where the company's long time CEO -- who is actually a 20-year-plus veteran of the business -- announced that the company is buying back nearly $3 billion worth of its own stock this year. If that's not a surefire sign that this company is 100% confident in its future, I don't know what is. But then again, I guess Wall Street's bearish stance actually makes perfect sense... Let's not forget, these are the same brand of just-got-my-MBA bozos that were pumping out headlines like "Things Look Really Bad For the Next 10 Years" and "Put Money in Banks, Not Stocks" back in August... Only to turn around two months later and crow about how, "The Best of Times for Stocks May Be Ahead" and "For Many Market Strategists, Equities Are Top Dog Again." Now, if I sound a little agitated, cynical, or even downright bitter, you'll have to forgive me... I'm just a little fed up with the tired old rollercoaster ride that folks like you and me have been duped into believing is sound financial "advice" -- and I imagine you probably feel the same way. Which is why I want to take a moment to tell you about the renegade investor who introduced me to this company and explain why he thinks that its now heavily discounted share price may well be... "The buying opportunity of the year" Of course, when I say "renegade" investor, I don't mean that this guy is some brash business-school dropout hell bent on riding rapid-fire options trades all the way to an estate in the Hamptons. I simply mean that he believes the only way to earn truly life-changing profits is to ignore most of what passes for conventional wisdom on Wall Street -- and actually do the exact opposite of what those stuffed shirts are doing. That's why you're infinitely more likely to find him talking about his favorite entertainment stock while playing a board game than bragging about how many of his stock picks have more than tripled since 2002 while schmoozing at some Upper East Side cocktail party (the number is 12, by the way). It's also why rather than putting all his faith in computerized stock screens, technical charts, and macro-economic models, he pounds the pavement to find the next world-changing product, invention, or innovation... And then develops an inside-out understanding of the companies behind them by interacting with their customers, employees, and senior management teams. It was this exact approach that led him to recommend Netflix to a group of dedicated investors who regularly seek his advice back in October 2004 when shares were selling for just $15.42. Unfortunately, his timing couldn't have been worse... You see, no sooner did he tell these investors to buy Netflix than a herd of Wall Street analysts came out and started squawking about how it was going to get run right out of business by the likes of Wal-Mart and Blockbuster. Shares of Netflix promptly plunged 23%. And most investors began dumping shares as fast as they could. But this guy isn't "most investors" and he certainly wasn't deterred -- partly because he knows that when it comes to making a killing in the stock market "timing" is never nearly as important as "time" is. And partly because he'd studied Netflix from the inside out and knew the company wasn't going anywhere... but up. So he went back to that same group of investors two months later and recommended they buy even more of the stock while it was selling for just $12 and change. Of course, as you probably know, Netflix recently hit an all-time high of $184.74 -- meaning investors who ignored the Wall Street herd and instead followed his advice have racked up gains in excess of 1,320%. Impressive? You bet it is. But make no mistake, this wasn't just some sort of fluke or lucky break... You see, this unique approach has also led him directly to companies like... | Priceline.com: | Up 1,318% | since he recommended it in May 2004 | | Hasbro: | Up 214% | since he recommended it in April 2003 | | Amazon.com: | Up 922% | since he recommended it in September 2002 | | Activision Blizzard: | Up 530% | since he recommended it March 2003 | Marvel:
(now a part of Walt Disney) | Up 1,565% | since he recommended it in July 2002 | Granted, not all of his picks wind up being such monster winners. And there's no denying he's picked a few losers, too. But over the past 8 years, his average stock pick has actually DOUBLED in value. So, I'm sure you can understand why anytime he gets excited about an investment opportunity I stand up and take notice. And I can tell you that, right now, he's extremely excited about the future of the company I've been telling you about today. In fact, he just put the finishing touches on a brand new premium research report entitled... "The Oxford Patent Profit Plan: Your Ticket to Riches Between Now and 2017" This reports contains everything you need to get invested in this incredible company today with 100% confidence -- including name, ticker symbol, detailed financial information, competitive analysis, and potential risks, as well as clear-cut instructions on when to buy and when to sell. Of course, as you may have guessed, premium reports like these are generally reserved for the group of investors I mentioned earlier. But as a special "thank you" for hearing me out today, I want to offer you the chance to not only get this valuable report absolutely free -- but also sample all of this investor's fortune-making research, stock picks, and insights with NO RISK OR OBLIGATION whatsoever. I'll explain how you can take me up on this unique offer in just a moment... But first, please allow me a proper introduction. My name is Austin Edwards. You may see my articles pop up from time to time in various financial publications, but I'm not a stock broker... a CFA... or an equity analyst... In fact, like you, I'm just a dedicated investor who's looking for the best way to grow my money into all the things I have worked so hard to achieve. Like the ability to travel to places most people only see on screen savers... or the time to work on writing projects that don't pay the bills... or even just the peace of mind that comes with knowing I'll be able to take care of my parents as well as they've taken care of me. And you know what? Despite my lack of formal financial training, I'm 100% confident I'll be able to do just that... Because over the past four years, I've had the privilege of working closely with not just one, but TWO of America's most trusted investors... I've already told you a little about the first one... about his "renegade" investing style... and about the monster winners it has led him to. Well, the second one is actually his brother... and although their personalities couldn't be more different, their results couldn't be more similar. You see, whereas his older brother looks for world-changing products and innovations, this guy likes to "fish where others aren't" -- and dig deep into a company's books to find hidden values and huge growth opportunities that Wall Street is overlooking. And this approach has allowed him to uncover little-known companies like... | Quality Systems: | Up 1,187% | since he recommended it in March 2003 | | Borg Warner: | Up 291% | since he recommended it in February 2004 | | Dolby Laboratories: | Up 203% | since he recommended it in November 2006 | | Lab Corp. of America: | Up 153% | since he recommended it August 2003 | | Teradata: | Up 133% | since he recommended it in May 2009 | Of course, by now you probably know I'm talking about Motley Fool co-founders David and Tom Gardner. After all, you may have read one of their eight best-selling investment books. Or perhaps you were one of the tens of thousands of people who regularly listened to their long-running NPR radio show... or read their nationally syndicated newspaper column. Or maybe you've just seen them on the cover of Fortune... or on TV talking stocks with people like Charlie Rose, Larry King, or Dr. Phil. Or you might just know that Money.com says they're "among the most widely-followed stock advisors in the world." Regardless, once you have a look at the incredible gains they're getting for investors like you and me, it's not hard to see why former SEC Chairman Arthur Levitt has said the Gardner brothers are... "As close to being an effective investor advocate as any organization in America..." Nor is it hard to see why thousands of investors just like you gladly pay good money to subscribe to their one-of-a-kind investment service, Motley Fool Stock Advisor. Especially when you consider that since launching the service in March 2002, David and Tom Gardner's average Stock Advisor pick is up a staggering 75%. 
Compare that with the measly 5% gain for the S&P 500 over the same period and you'll begin to understand why dozens of David and Tom's Motley Fool Stock Advisor members routinely email them to say things like... "I have been a Stock Advisor subscriber since the beginning. This has been such a good investment for my family. I feel so much more secure about our future." -- Dennis I., Glendale, AZ
"I hope that you continue to provide Stock Advisor for the next 30 years. Because of you guys many people will truly be able to enjoy their retirement." -- David B., Chicago, IL If that's not proof of the enormously positive impact Motley Fool Stock Advisor can have on your wealth, I don't know what is. But I don't want you to have to take my word for it... Instead I'd like to actually give you the opportunity to sample everything Motley Fool Stock Advisor has to offer with absolutely NO RISK or OBLIGATION for 30 FULL DAYS starting right now. That way you can not only get a copy of David Gardner's brand-new report, "The Oxford Patent Profit Plan: Your Ticket to Riches Between Now and 2017" absolutely free... But you can also take a FULL 30 DAYS to... - explore the exclusive, password-protected Stock Advisor website...
- read up on all of David and Tom Gardner's current and past stock recommendations...
- dig through all of their in-depth stock research...
- download all of their premium research reports...
- and comb through the exclusive members-only discussion boards -- where you'll discover investment insights you simply won't find anywhere else.
And if after a month you're not 100% convinced that Motley Fool Stock Advisor can help you grow your hard-earned money into a lasting fortune -- or you just don't feel it's right for you -- simply call our dedicated customer service team. They work right down the hall from David and Tom Gardner and will be happy to promptly and courteously refund every last cent -- no questions asked. And should you want to cancel at any point after your first month, that's fine, too. They'll happily refund the full dollar value of the remainder of your membership term. Again, no questions asked. But I must insist on one point... Regardless of how long you're with Stock Advisor, your copy of "The Oxford Patent Profit Plan"... plus all the valuable research and reports you can access on the Stock Advisor members-only website... plus two bonus reports valued at over $98 (full details just ahead) ARE ALL YOURS TO KEEP.
This is The Motley Fool's "Keep Everything" & "Risk Nothing" DOUBLE GUARANTEE It's also David and Tom Gardner's way of saying "thank you" for giving Motley Fool Stock Advisor an honest shot at helping you achieve your financial dreams. Of course, this kind of guarantee makes it possible for you to snap up everything I've mentioned today and not pay a single cent. And that's fine with David and Tom. That's how confident they are that their hard work and diligence can help make you some serious profits... and how sure they are that once you see everything Stock Advisor has to offer, you'll want to stick around for the long haul. Speaking of which, let's quickly review everything you'll get when you accept my invitation today... For starters, I'll send you your very own copy of "The Oxford Patent Profit Plan" so you can position yourself to cash in on the incredible growth opportunity I've told you about today with 100% CONFIDENCE. Plus, as an added bonus, I'll send you another of our most valuable Stock Advisor premium reports -- which reveals the full details on one of the few stocks that both David and Tom Gardner are recommending investors snap up right away. Have a look... You'll also have access to everything on our exclusive password-protected, members-only website, including... - Live Interactive Scorecard -- Constantly updated throughout the trading day, so you can see exactly how every Stock Advisor pick is doing relative to the S&P 500. Plus, simply click on any stock to find in-depth research write-ups, updates, discussion boards, and much more.
- Easy-to-Use "My Scorecard" Feature -- A hassle-free way to accurately track the performance of every Stock Advisor pick in your portfolio -- so you'll always know exactly how much money Stock Advisor has made you.
- Weekly Updates -- So you'll have all the important information you need, from when to buy and sell to analysis of specific developments that affect your money. And, of course, access to all previous updates is never more than a click away.
- 24/7 Access to All Back Issues -- So you can easily get the full story on all our past Stock Advisor recommendations -- when it's convenient for you.
- Lively Discussion Boards -- Where you can get the inside story on a stock directly from the candid experiences of the company's employees, customers, and investors. You can also post questions or talk stocks with other members and the Stock Advisor team at any hour of the day -- all from the comfort of your home.
Then, on the third Friday of every month you're with us, you'll receive an email alerting you that a brand-new issue of Motley Fool Stock Advisor is available online. You can download and print this electronic issue anytime you like -- and, for your convenience, we'll also mail a hard copy directly to your home or office. Each new Stock Advisor issue contains the full story on not one -- but TWO -- breakout stocks that David and Tom Gardner are convinced can help you lock down some serious profits. And every Stock Advisor recommendation comes with an in-depth research write-up -- including company profile, product descriptions, competitive analysis, risk analysis, and discussion of the company's finances and sales prospects. Some advisory services charge thousands of dollars for access to premium services like this And you might think that David and Tom Gardner would, too -- especially considering that their average Stock Advisor pick is up 75%. But believe it or not, you can put David and Tom Gardner and the entire Motley Fool Stock Advisor team to work for you for a mere fraction of that. In fact, normally you can join Motley Fool Stock Advisor for just $199 per year. I think you'll agree that's a bargain in itself, considering all the valuable wealth-building tools and fortune-making stock picks you'll have access to. Neil A. of Brookline, MA, certainly seems to think so. He recently wrote us to say: "Paying for your services is the best money I spend, and I extract FAR more value than I am paying in. You can take the profit from any of the big winners I have bought because of you guys and that alone more than covers the cost." But, because times are tough and opportunities like the one I told you about simply don't wait for anyone, I've arranged an even better deal for you. So, when you join us right now through this personal invitation, you can go ahead and knock a FULL $120 off the regular membership price. That's 60% LESS than many other investors have gladly paid. It's also the lowest price we can possibly offer. And when you do the math, it comes out to just $1.51 per week. Just think, with that kind of pocket change, you can either buy yourself a cup of coffee (if you're lucky!)... or discover stocks like these -- before the masses do... - Marvel: Up 1,565% and counting
- GameStop: Locked in 137% gains
- Quality Systems: Up 1,187% and counting
- Affiliated Managers Group: Locked in 224% gains
- Priceline.com: Up 1,318% and counting
And don't forget, this private invitation entitles you to sample everything Motley Fool Stock Advisor has to offer for a full 30 days -- with no risk or obligation whatsoever! Plus, when you join David and Tom Gardner at Motley Fool Stock Advisor right now, you'll also get immediate access to one of the most comprehensive and timely investment reports we've ever put together here at The Motley Fool. Have a look... Add it up and your free special reports and discounts total more than $245 Yet you'll only pay a fraction of that -- and you won't have to risk even one dime. In other words, you have everything to gain -- but absolutely nothing to lose. Of course, there is one catch... I can only guarantee everything I've offered you today if you join us RIGHT NOW THROUGH THIS EMAIL. But more importantly, time is of the absolute essence when it comes to unique wealth-building opportunities like the one we've discussed today. So please don't risk missing out. Simply click the "START NOW" button to the right and begin profiting today! Do it now. I look forward to hearing from you soon. Good investing,  Austin Edwards Senior Investment Writer, The Motley Fool P.S. Remember, this is a unique win-win proposition because you're covered by our special "keep everything and risk nothing" DOUBLE GUARANTEE. P.P.S. All of our competitors think we're crazy to offer so many bonuses even if people don't join us for the long haul. But we're that confident that once you see the difference Motley Fool Stock Advisor can make, you won't know how you invested without it. P.P.P.S. Don't forget, to take advantage of this remarkable offer, you must join through this email today! All scorecard returns as of October 14, 2010. Unless otherwise noted, all figures as of October 27, 2010. | 
